Men who are carriers of a BRCA2 pathogenic variant were more likely to develop breast, prostate, and pancreatic cancers than patients harboring BRCA1, according to an analysis of male and female carriers of BRCA1/2 pathogenic variants.
According to the CDC, patients at any age who have cancer are at an increased risk of severe illness due to coronavirus disease 2019 (COVID-19), and this may be aggravated by aspects such as race, ethnicity, and socioeconomic factors.
As the new chair of the 17th Annual International Society of Gastrointestinal Oncology meeting, Tanios Bekaii-Saab, MD, said that this year’s virtual conference will place particular emphasis on fellows’ education and involvement.
Research into mutations in the gene encoding the epidermal growth factor receptor protein has revolutionized non–small cell lung cancer treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.
Prostate-specific antigen changes were observed 6 weeks after the administration of 177Lu-PSMA in men with metastatic castration-resistant prostate cancer, suggesting a prognostic value for long-term clinical benefit, according to a single center retrospective analysis.